TY - JOUR
T1 - Evaluation and characterization of HSPA5 (GRP78) expression profiles in normal individuals and cancer patients with COVID-19
AU - Fu, Jiewen
AU - Wei, Chunli
AU - He, Jiayue
AU - Zhang, Lianmei
AU - Zhou, Ju
AU - Balaji, Kyathegowdanadoddi Srinivasa
AU - Shen, Shiyi
AU - Peng, Jiangzhou
AU - Sharma, Amrish
AU - Fu, Junjiang
N1 - Funding Information:
This work was supported in part by the National Natural Science Foundation of China (81672887 and 30371493), the Joint Research Foundation of Luzhou City and Southwest Medical University (2018LZXNYD-YL01), and The Translational Medicine Foundation of Southwest Medical University (grant nos. 00031476 and 00031477) to JF.
Publisher Copyright:
© The author(s).
PY - 2021
Y1 - 2021
N2 - HSPA5 (BiP, GRP78) has been reported as a potential host-cell receptor for SARS-Cov-2, but its expression profiles on different tissues including tumors, its susceptibility to SARS-Cov-2 virus and severity of its adverse effects on malignant patients are unclear. In the current study, HSPA5 has been found to be expressed ubiquitously in normal tissues and significantly increased in 14 of 31 types of cancer tissues. In lung cancer, mRNA levels of HSPA5 were 253-fold increase than that of ACE2. Meanwhile, in both malignant tumors and matched normal samples across almost all cancer types, mRNA levels of HSPA5 were much higher than those of ACE2. Higher expression of HSPA5 significantly decreased patient overall survival (OS) in 7 types of cancers. Moreover, systematic analyses found that 7.15% of 5,068 COVID-19 cases have malignant cancer coincidental situations, and the rate of severe events of COVID-19 patients with cancers present a higher trend than that for all COVID-19 patients, showing a significant difference (33.33% vs 16.09%, p<0.01). Collectively, these data imply that the tissues with high HSPA5 expression, not low ACE2 expression, are susceptible to be invaded by SARS-CoV-2. Taken together, this study not only indicates the clinical significance of HSPA5 in COVID-19 disease and cancers, but also provides potential clues for further medical treatments and managements of COVID-19 patients.
AB - HSPA5 (BiP, GRP78) has been reported as a potential host-cell receptor for SARS-Cov-2, but its expression profiles on different tissues including tumors, its susceptibility to SARS-Cov-2 virus and severity of its adverse effects on malignant patients are unclear. In the current study, HSPA5 has been found to be expressed ubiquitously in normal tissues and significantly increased in 14 of 31 types of cancer tissues. In lung cancer, mRNA levels of HSPA5 were 253-fold increase than that of ACE2. Meanwhile, in both malignant tumors and matched normal samples across almost all cancer types, mRNA levels of HSPA5 were much higher than those of ACE2. Higher expression of HSPA5 significantly decreased patient overall survival (OS) in 7 types of cancers. Moreover, systematic analyses found that 7.15% of 5,068 COVID-19 cases have malignant cancer coincidental situations, and the rate of severe events of COVID-19 patients with cancers present a higher trend than that for all COVID-19 patients, showing a significant difference (33.33% vs 16.09%, p<0.01). Collectively, these data imply that the tissues with high HSPA5 expression, not low ACE2 expression, are susceptible to be invaded by SARS-CoV-2. Taken together, this study not only indicates the clinical significance of HSPA5 in COVID-19 disease and cancers, but also provides potential clues for further medical treatments and managements of COVID-19 patients.
KW - Cancer
KW - HSPA5
KW - Prognostics
KW - SARS-CoV-2
KW - Transcriptomics
UR - http://www.scopus.com/inward/record.url?scp=85102754215&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102754215&partnerID=8YFLogxK
U2 - 10.7150/ijbs.54055
DO - 10.7150/ijbs.54055
M3 - Article
C2 - 33767597
AN - SCOPUS:85102754215
SN - 1449-2288
VL - 17
SP - 897
EP - 910
JO - International journal of biological sciences
JF - International journal of biological sciences
IS - 3
ER -